Alpha‑1 Antitrypsin Deficiency: Evidence‑Based Clinical Recommendations

1. Disease Overview

• Alpha‑1 antitrypsin (AAT) deficiency is an autosomal codominant disorder that produces markedly reduced serum AAT levels and confers a high risk of early‑onset pan‑lobular basal emphysema and liver cirrhosis. 1

2. Genetics and Molecular Pathophysiology

2.1 Gene Structure

• The SERPINA1 gene resides on chromosome 14q32.13, spans ~14 kb, contains seven exons (four coding), and encodes a 394‑amino‑acid protein. 2

2 .2 Common Alleles

• The most frequent pathogenic allele is Pi*Z (c.1096G>A, p.Glu342Lys). 3
• The Pi*S allele (c.863A>T, p.Glu264Val) is the second most common variant. 3
• The normal protein phenotype is designated M (Pi*M). 1
• Null mutations result in complete absence of circulating AAT. 3

2.3 Pathogenic Mechanisms

• Severe AAT deficiency leaves neutrophil elastase unchecked, leading to elastic tissue destruction and basal pan‑lobular emphysema. 1
• The Pi*Z mutation causes misfolding and polymerization of AAT, reducing hepatic secretion and causing intra‑hepatocellular polymer accumulation, which drives liver disease. 3
• Polymerized AAT is a key factor in the pathogenesis of AAT‑related liver disease. 4
• Null mutations do not predispose to liver disease because no polymer accumulates. 5
• Lifetime risk of cirrhosis in deficient individuals is approximately 30–40 %. 4

2.4 Modifying Risk Factors

• Cigarette smoking is the strongest environmental factor accelerating emphysema progression. 1

3. Diagnosis

3.1 Recommended Diagnostic Algorithm

• In patients with high clinical suspicion, perform comprehensive SERPINA1 exon sequencing rather than limited targeted genotyping. 6
• When suspicion is moderate, first measure serum AAT level; if low, proceed to genetic testing. 6

3.2 Diagnostic Modalities

• Serum iso‑electric focusing (IEF) phenotyping has historically been the gold standard for AAT deficiency detection. 5
• Exon sequencing identifies all coding SERPINA1 mutations in a single assay. 2
• Targeted genotyping can miss many pathogenic variants and should be used only when a specific mutation is pre‑identified. 2

3.3 Nomenclature Standards

• Genetic test reports should follow Human Genome Variation Society (HGVS) nomenclature. 6
• During transition, dual reporting (HGVS + Pi) is advised; the Pi system may become obsolete. 6

3.4 Family Screening

• Offer genetic counseling and AAT testing to first‑degree relatives of any individual with an abnormal SERPINA1 result (heterozygous or homozygous). 6
• Patients harboring novel mutations should be referred to an expert reference center. 6

4. Clinical Manifestations

4.1 Pulmonary Disease

• Homozygous Pi*ZZ individuals have profoundly low serum AAT and a markedly increased risk of COPD presenting as basal pan‑lobular emphysema. 7
• Bronchiectasis (both saccular and cylindrical) is associated with AAT deficiency. 4
• Adult‑onset asthma with persistent airflow obstruction can be a manifestation. 1

4.2 Hepatic Disease

• Only ~2.5 % of newborns with PiZZ die from acute liver failure, but PiZZ is a common cause of neonatal cholestasis. 4
• Cirrhosis may appear at any age; the highest incidence is in older, never‑smoked individuals who survived without severe emphysema. 5
• Hepatocellular carcinoma can develop in cirrhotic livers of AAT‑deficient patients. 4

4.3 Extra‑Pulmonary/Extra‑Hepatic Manifestations

• Necrotizing panniculitis is a rare but recognized complication. 5
• AAT deficiency is linked to C‑ANCA‑positive vasculitis (e.g., granulomatosis with polyangiitis). 5
• Current evidence does not support associations with intracranial or abdominal aortic aneurysms, pancreatitis, or celiac disease. 5

5. Management

5.1 General Pulmonary Care

• All patients with respiratory involvement should receive smoking cessation counseling, annual influenza vaccination, pneumococcal vaccination every five years, pulmonary rehabilitation, self‑management education, supplemental oxygen when indicated, coordinated case management, and appropriate surgical referral. 7

5.2 Augmentation Therapy (Intravenous AAT)

• Indicated for individuals with FEV₁ < 80 % predicted and radiographic emphysema to slow loss of lung density. 8
• Evidence derives from concordant observational studies; no randomized controlled trial has definitively proven efficacy. 5
• Greatest benefit observed in patients with moderate obstruction (FEV₁ 35–60 % predicted); benefit is less clear in severe (FEV₁ < 35 %) or mild obstruction. 5
• Not recommended for patients without radiographic emphysema. 5
• Uncertainty remains regarding benefit for patients without FEV₁ decline or for those with asthma/bronchiectasis but no CT‑proven emphysema. 2

5.3 Hepatic Management

• No disease‑modifying therapy exists for AAT‑related liver disease aside from liver transplantation in end‑stage cases; augmentation therapy does not improve hepatic outcomes. 5
• Management includes hepatitis A/B vaccination, regular physical examination, liver‑function testing, and surveillance ultrasound. 5
• For patients ≥ 50 years with decompensated cirrhosis and elevated hepatocellular carcinoma risk, periodic liver CT is advised. 5
• Asymptomatic older individuals should undergo routine simple liver‑function tests. 5

5.4 Emerging Therapies (Research Directions)

• Strategies under investigation include enhancing autophagy of polymerized AAT, RNA interference or editing, and gene‑transfer approaches. [8][5]

Management of Alpha‑1 Antitrypsin Heterozygous Carriers

Genetic Modifiers and Hepatic Risk

• In heterozygous carriers, the presence of additional hepatotoxic factors (e.g., viral hepatitis, alcohol use) can worsen liver disease outcomes, indicating that carriers may act as genetic modifiers for liver injury【9】.
• Carriers do not typically develop necrotizing panniculitis or C‑ANCA‑positive vasculitis, conditions that are linked to severe AAT deficiency【10】.

Reproductive Counseling and Risk Assessment

• When both parents are heterozygous carriers (e.g., PiMZ), each pregnancy carries a *25 % risk* of a child with severe AAT deficiency (PiZZ)【10】【11】.
• The same parental combination confers a 50 % risk of the offspring being a carrier (PiMZ)【11】 and a *25 % chance* of a normal genotype (PiMM)【10】.
• Professional societies assign a Type B recommendation to assess carrier status in the context of reproduction, endorsing pre‑conception counseling and partner testing【10】【11】.
• Prenatal (fetal) testing for AAT deficiency receives a Type D recommendation (not recommended); instead, emphasis should be placed on pre‑conception counseling and partner screening【10】【11】.

Screening and Monitoring Recommendations

• Routine spirometry or liver‑function testing is not indicated for asymptomatic carriers who lack additional risk factors (e.g., smoking, occupational exposures)【10】.
• If a carrier develops unexplained COPD, emphysema (particularly with basilar predominance), or liver disease, a full diagnostic work‑up should be undertaken to evaluate possible phenotypic expression or co‑existing pathology【12】.
• Carriers who have persistent airflow obstruction together with identifiable risk factors (such as tobacco smoking or occupational irritant exposure) should receive closer clinical monitoring【10】.

Population Screening and Family Testing

• Population‑wide screening for AAT carrier status is not recommended (Type D recommendation); however, targeted testing of first‑degree relatives of known carriers is considered a highly efficient strategy for case detection【10】【11】.